<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of chronic hepatitis B in patients with HIV
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of chronic hepatitis B in patients with HIV
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of chronic hepatitis B in patients with HIV
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth E Sherman, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Chloe L Thio, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David L Thomas, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 02, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1427865172">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of potent antiretroviral therapy (ART) to treat HIV infection has led to declining rates of opportunistic infections and the need to manage other causes of morbidity in individuals with HIV, such as end-stage liver disease secondary to chronic hepatitis B virus (HBV) infection. The treatment and prevention of HBV infection has taken on great significance in light of the negative impact HIV has on the natural history of chronic HBV infection. In coinfected patients, HBV infection is best treated with oral antiviral agents that can also be used to treat HIV. Once initiated, they are continued indefinitely in most individuals to maintain suppression of both viruses.
        </p>
        <p>
         This topic will review the treatment of chronic HBV infection in patients with HIV. Other relevant topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3640.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of hepatitis B in patients living with HIV"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16127.html" rel="external">
          "Pretreatment evaluation of chronic hepatitis B virus infection in the patient with HIV"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16129.html" rel="external">
          "Monitoring the patient with HIV and chronic hepatitis B virus infection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15807.html" rel="external">
          "Prevention of hepatitis B virus infection in adults with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H489595252">
         <span class="h1">
          RATIONALE FOR TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV and chronic HBV infection should receive treatment to suppress both viruses regardless of HBV DNA level or degree of liver damage [
         <a href="#rid1">
          1-5
         </a>
         ]. Chronic HBV infection is defined as a positive (ie, reactive) hepatitis B surface antigen (HBsAg) on two occasions at least six months apart.
        </p>
        <p>
         This approach to treatment differs from that used in patients who have HBV monoinfection, in which the decision to initiate therapy is based upon the blood HBV DNA level, as well as the degree of liver damage and inflammation. (See
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management"
         </a>
         .)
        </p>
        <p>
         The rationale for the difference in treatment of chronic HBV infection in persons with HIV is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevent HIV and HBV drug resistance – Guidelines for the treatment of adults with HIV recommend antiretroviral therapy (ART) for all patients, regardless of CD4 cell count [
         <a href="#rid1">
          1,5
         </a>
         ]. Certain antiretroviral agents used to treat HIV are also used to treat HBV. As a result, coinfected patients may be initiated on medications for their HIV that have activity against HBV. To prevent the development of HIV and/or HBV drug resistance, it is important that both infections be optimally treated at the same time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Slow progression of chronic HBV infection, which has an accelerated course in coinfected patients – The course of chronic HBV infection is accelerated in patients with HIV and treatment may reduce the risk of disease progression [
         <a href="#rid6">
          6-8
         </a>
         ]. HIV/HBV-coinfected patients have faster progression of fibrosis and an increased risk of cirrhosis, end-stage liver disease, and hepatocellular carcinoma compared with HBV-monoinfected patients [
         <a href="#rid9">
          9-13
         </a>
         ]. This may be due, in part, to less immunologic control of HBV infection, which is reflected by the higher levels of HBV DNA in coinfected compared with monoinfected patients [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Liver-related mortality is also greater in coinfected individuals compared with patients with HIV or chronic HBV infection alone [
         <a href="#rid14">
          14-16
         </a>
         ]. As an example, in a cohort study of men with HIV, individuals with HIV/HBV coinfection were approximately 17 times more likely to die of liver-related causes compared with those with HBV monoinfection [
         <a href="#rid14">
          14,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3640.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of hepatitis B in patients living with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduce the incidence of immune reconstitution inflammatory syndrome (IRIS) – By treating both HIV and HBV concurrently, it may be possible to reduce the incidence of an IRIS. In patients with advanced immunosuppression (ie, CD4 cell count &lt;200 cells/microL), initiating ART in a patient not treated for HBV infection may result in acute hepatitis due to immune reconstitution (see
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome", section on 'IRIS associated with hepatitis B and C'
         </a>
         ). Although no studies have evaluated whether or not the incidence of IRIS is reduced by treating both infections simultaneously, there is a theoretical benefit since the risk of IRIS related to HBV infection is increased in patients with high levels of HBV viremia [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Patients with occult hepatitis B should also receive treatment to suppress both viruses. Such patients have a detectable HBV DNA and a positive hepatitis B core antibody (anti-HBc), but have negative serologies for HBsAg on two occasions at least six months apart (ie, they do not have resolving or chronic HBV). The clinical significance of occult hepatitis B in individuals with HIV is not clear [
         <a href="#rid19">
          19
         </a>
         ]. However, in a patient with occult hepatitis B, it is important that an HIV regimen be fully active against HBV to prevent the development of drug-resistant HBV. (See
         <a class="local">
          'Approach to treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H250145399">
         <span class="h1">
          EVALUATION PRIOR TO HBV TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pretreatment evaluation of patients with chronic HBV and HIV coinfection includes a detailed history and physical examination to assess for hepatotoxic medications and evidence of advanced liver disease; laboratory testing to evaluate markers of HBV activity, kidney function, liver function, and coexisting causes of liver disease; testing to determine the stage and activity of liver disease; and ultrasound imaging to screen for evidence of hepatocellular carcinoma. In addition, a baseline HBV resistance panel is sometimes obtained in patients with prior exposure to
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         or
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         since HBV resistance has been reported in patients using these agents (especially if they were used as monotherapy). A detailed discussion of the pretreatment evaluation of patients with HIV/HBV coinfection is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16127.html" rel="external">
          "Pretreatment evaluation of chronic hepatitis B virus infection in the patient with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1385079">
         <span class="h1">
          ANTIVIRAL MEDICATIONS FOR HBV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tenofovir,
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         (and the closely related agent,
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         ),
         <a class="drug drug_general" data-topicid="9488" href="/z/d/drug information/9488.html" rel="external">
          telbivudine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8690" href="/z/d/drug information/8690.html" rel="external">
          adefovir
         </a>
         are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that can suppress hepatitis B virus (HBV) DNA, prevent or slow the development of hepatic complications, and decrease liver-related death [
         <a href="#rid20">
          20-23
         </a>
         ]. All are renally metabolized. The doses of these agents should be reduced for patients with reduced kidney function and are described in the individual drug monographs within UpToDate.
        </p>
        <p class="headingAnchor" id="H1585027495">
         <span class="h2">
          Tenofovir
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tenofovir is a nucleotide reverse transcriptase inhibitor with activity against HIV and HBV. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Tenofovir'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3656.html" rel="external">
          "Tenofovir and adefovir for the treatment of chronic HBV infection"
         </a>
         .)
        </p>
        <p>
         Tenofovir is considered a first-line agent for patients with chronic HBV infection because the virologic efficacy is high and the risk of HBV resistance is low; it is also active against lamivudine-resistant HBV [
         <a href="#rid24">
          24-29
         </a>
         ]. In a meta-analysis of HIV/HBV-coinfected patients,
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         (TDF) suppressed HBV DNA to undetectable levels in approximately 90 percent of coinfected patients, with the proportion increasing rapidly over the first two years, and then slowly rising after that [
         <a href="#rid20">
          20
         </a>
         ]. HBV resistance to TDF is uncommon, but a quadruple mutation has been described in two patients that increased the IC50 to tenofovir 1.3-fold [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Tenofovir is available in two preparations, TDF and
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         (TAF). Both agents are available as part of several different coformulated tablets  (
         <a class="graphic graphic_table graphicRef60927" href="/z/d/graphic/60927.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         On occasion, TDF can lead to renal impairment (characterized by increases in serum creatinine, proteinuria, glycosuria, increased urinary phosphorous excretion, hypophosphatemia, and acute tubular necrosis), as well as bone loss. The TAF formulation is associated with less renal toxicity and has less effect on bone density [
         <a href="#rid31">
          31,32
         </a>
         ], but may been associated with increased metabolic complications such as weight gain and higher cholesterol [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Commonly used agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Tenofovir'
         </a>
         .)
        </p>
        <p>
         Both TDF and TAF have been found to be effective in suppressing HIV and HBV [
         <a href="#rid34">
          34-37
         </a>
         ]. In a study of 72 HIV/HBV-coinfected patients who switched from a fully suppressive HIV regimen to EVG/c/FTC/TAF, 92 percent either maintained or achieved suppression of HIV and HBV over 48 weeks [
         <a href="#rid37">
          37
         </a>
         ]. In addition, two large randomized trials of HBV monoinfected patients found that TAF was noninferior to TDF for the treatment of HBV in both treatment-naïve and treatment-experienced patients [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4288219402">
         <span class="h2">
          Entecavir
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          Entecavir
         </a>
         is a potent inhibitor of hepatitis B polymerase that results in greater HBV suppression compared with
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         . Although HBV resistance to entecavir rarely develops in patients who are HBV treatment-naïve, the risk increases in patients with lamivudine-resistant HBV (approximately 50 percent after five years of treatment) [
         <a href="#rid40">
          40
         </a>
         ]. Thus, this agent is generally not used for patients with evidence of (or concerns for) lamivudine-resistant HBV. (See
         <a class="local">
          'Approach to treatment'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          Entecavir
         </a>
         monotherapy for HBV is not recommended in patients with HIV unless it is used in combination with a fully active antiretroviral (ART) regimen to treat HIV. Entecavir has anti-HIV activity that results in an approximate one-log drop in HIV RNA, and when entecavir monotherapy is administered to HIV/HBV-coinfected patients, the M184V HIV resistance mutation can develop [
         <a href="#rid29">
          29,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We typically administer
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         as 1.0 mg/day to all patients, since there is a low risk of toxicity. However, other providers only administer this dose to patients with lamivudine-resistant virus and/or cirrhosis, and use a lower dose (0.5 mg/day) of entecavir for HBV treatment-naïve patients without cirrhosis. (See
         <a class="medical medical_review" href="/z/d/html/3653.html" rel="external">
          "Entecavir in the treatment of chronic hepatitis B virus infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3671809659">
         <span class="h2">
          Lamivudine/emtricitabine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          Lamivudine
         </a>
         and
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         are closely related agents that are used to treat HIV and have demonstrated efficacy against HBV infection in both hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients [
         <a href="#rid41">
          41-44
         </a>
         ]. However, in people with HIV, they should not be used without TDF or TAF since they have a low genetic barrier to HBV resistance. Management of patients who cannot take tenofovir is discussed below. (See
         <a class="local">
          'If tenofovir should not be used'
         </a>
         below.)
        </p>
        <p>
         The development of
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         resistant HBV in HIV/HBV-coinfected patients has been associated with duration of treatment; no relationship between baseline HBV DNA level, aminotransferases, or CD4 cell count has been seen [
         <a href="#rid41">
          41,45,46
         </a>
         ]. As an example, in a retrospective analysis of 81 chronically infected HIV/HBV-coinfected patients receiving lamivudine monotherapy for HBV, lamivudine-resistant HBV developed in approximately 50 percent after two years and more than 90 percent after four years of treatment [
         <a href="#rid45">
          45
         </a>
         ]. The onset of lamivudine resistance has been associated with exacerbations of hepatitis and hepatic failure [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         The primary
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         resistance mutations are located at rtM204, with the methionine replaced by either an isoleucine or a valine (rtM204V/I) [
         <a href="#rid48">
          48
         </a>
         ]. Secondary compensatory mutations may also occur in association with rtM204V/I, and certain ones (ie, rtI169T, rtS202I, and rtT184S/G) can contribute to
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         resistance. The rtA181T mutation can occur in the absence of rtM204V/I and can confer resistance to
         <a class="drug drug_general" data-topicid="8690" href="/z/d/drug information/8690.html" rel="external">
          adefovir
         </a>
         as well [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H712359598">
         <span class="h2">
          Less commonly used agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pegylated interferon alfa can also be used to treat HBV but is not commonly used in patients with HIV. (See
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management", section on 'Overview of antiviral agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H489595324">
         <span class="h1">
          APPROACH TO TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H712359220">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV and chronic HBV infection should receive treatment to suppress both viruses regardless of HBV DNA level or degree of liver damage [
         <a href="#rid1">
          1-5
         </a>
         ]. Such patients should be treated with a regimen that is effective against
         <strong>
          both
         </strong>
         HBV and HIV. (See
         <a class="local">
          'Rationale for treatment'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients, we administer a regimen that includes tenofovir. Tenofovir is effective for the treatment of HBV in both treatment-naïve and treatment-experienced patients (eg, those who have received
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         , or
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         ), including those with lamivudine-resistant HBV. It is also a first-line agent for the treatment of HIV. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Tenofovir is available in two preparations,
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         (TDF) and
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         (TAF). Both agents are effective for the treatment of HBV and HIV. Although there is more experience with TDF, there is less toxicity associated with the TAF formulation. (See
         <a class="local">
          'Tenofovir'
         </a>
         above and
         <a class="local">
          'Preferred regimens'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          Entecavir
         </a>
         may be a suitable alternative in select settings when tenofovir should not be used. (See
         <a class="local">
          'If tenofovir should not be used'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, if
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         is used, it must be administered in conjunction with a fully active HIV antiretroviral (ART) regimen, since entecavir, although partially active against HIV, lacks significant virologic potency and can lead to the development of the HIV drug-resistant mutation M184V. If entecavir is used, we prefer a nucleoside-sparing ART regimen. (See
         <a class="local">
          'Entecavir'
         </a>
         above and
         <a class="local">
          'When entecavir is used'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We
         <strong>
          avoid
         </strong>
         an HIV ART regimen that uses
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         or
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         monotherapy for the treatment of HBV (eg, one that uses
         <a class="drug drug_general" data-topicid="9010" href="/z/d/drug information/9010.html" rel="external">
          abacavir-lamivudine
         </a>
         as the nucleoside combination or the use of a two-drug regimen such as
         <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">
          dolutegravir-lamivudine
         </a>
         ) because of the rapid emergence of lamivudine-resistant HBV due to a mutation within the YMDD motif (rtM204V) of HBV reverse transcriptase [
         <a href="#rid41">
          41,46
         </a>
         ]. (See
         <a class="local">
          'Lamivudine/emtricitabine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         On rare occasion, concurrent treatment of HIV and HBV may not be possible (eg, patient refuses HIV therapy). Although this scenario should be discouraged, pegylated interferon alfa (PegIFN) can be used for the treatment of HBV since PegIFN does not induce HIV drug resistance. A more detailed discussion of interferon therapy for HBV is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3661.html" rel="external">
          "Pegylated interferon for treatment of chronic hepatitis B virus infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2306193528">
         <span class="h2">
          Preferred regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend a tenofovir-containing regimen for the treatment of HIV and HBV in almost all patients with HIV/HBV coinfection. There are only rare instances in which an alternative regimen should be considered (eg, patients with a history of a severe adverse reaction to TDF, those with an estimated glomerular filtration rate [eGFR] &lt;15 mL/min/1.73 m
         <sup>
          2
         </sup>
         who are not receiving dialysis, and those with severe osteoporosis). (See
         <a class="local">
          'If tenofovir should not be used'
         </a>
         below.)
        </p>
        <p>
         In general, we administer one of the following tenofovir-containing ART regimens:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          Dolutegravir
         </a>
         plus
         <a class="drug drug_general" data-topicid="107645" href="/z/d/drug information/107645.html" rel="external">
          tenofovir alafenamide-emtricitabine
         </a>
         (TAF/FTC)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="116731" href="/z/d/drug information/116731.html" rel="external">
          Bictegravir-emtricitabine-tenofovir alafenamide
         </a>
         (BIC/FTC/TAF)
        </p>
        <p>
        </p>
        <p>
         Detailed discussions of how to select an ART regimen are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13979.html" rel="external">
          "Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"
         </a>
         .)
        </p>
        <p>
         In some cases, TAF may not be available or should be avoided because of drug interactions (eg, certain anticonvulsants). In these settings, TDF can be used instead of TAF (eg,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         plus TDF/FTC) if the patient has normal kidney function (eGFR ≥60 mL/min/1.73 m
         <sup>
          2
         </sup>
         ). There is extensive experience with TDF for the treatment of HBV and HIV. However, the risk of kidney disease (eg, proximal tubular injury and worsening chronic kidney disease) and bone loss is greater with TDF compared with TAF. (See
         <a class="local">
          'Tenofovir'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Tenofovir'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3805712880">
         <span class="h2">
          Special considerations
         </span>
        </p>
        <p class="headingAnchor" id="H4142285761">
         <span class="h3">
          Tenofovir in patients with reduced kidney function
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with reduced kidney function (estimated glomerular filtration rate [eGFR] &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         ), we make all efforts to administer a tenofovir-containing ART regimen. Tenofovir (particularly TDF) has been associated with renal dysfunction; however, this is less likely to occur with TAF. Our general approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with an eGFR ≥30 mL/min/1.73 m
         <sup>
          2
         </sup>
         , an ART regimen that includes TAF should be used. (See
         <a class="local">
          'Preferred regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with more severely reduced kidney function, our approach depends upon the degree of renal insufficiency:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with an eGFR ≥15 mL/min/1.73 m
         <sup>
          2
         </sup>
         and those on hemodialysis, we administer an ART regimen that includes TAF/FTC. (See
         <a class="local">
          'Preferred regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Although some guidelines suggest that the combination of TAF/FTC be avoided in patients with an eGFR &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         who are not on hemodialysis [
         <a href="#rid5">
          5
         </a>
         ], we feel comfortable using this regimen for patients with HIV/HBV coinfection and an eGFR ≥15 mL/min/1.73 m
         <sup>
          2
         </sup>
         , since TAF monotherapy is approved for patients with an eGFR in this range and there are data supporting the safety of regimens containing TAF/FTC in patients on hemodialysis [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with HIV and an eGFR &lt;15 mL/min/1.73 m
         <sup>
          2
         </sup>
         who are
         <strong>
          not
         </strong>
         on hemodialysis, there are insufficient safety data to recommend TAF in combination with FTC. Since TAF achieves high intracellular concentrations, there could be a potential increased risk of toxicity (eg, lactic acidosis/severe hepatomegaly with steatosis), particularly when the two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are coadministered. Thus, for this group, optimal treatment sometimes involves complex tradeoffs, such as the risk of toxicity with TAF or worsening kidney function with dose-reduced TDF versus the risk of treatment failure with an alternative agent. (See
         <a class="local">
          'If tenofovir should not be used'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         If TAF is not available or should not be used, patients should be managed in conjunction with a provider experienced in the treatment of HIV and HBV.
        </p>
        <p class="headingAnchor" id="H3029510134">
         <span class="h3">
          If tenofovir should not be used
         </span>
         <span class="headingEndMark">
          —
         </span>
         On rare occasion, a tenofovir-containing ART regimen cannot be used (eg, adverse reaction to tenofovir) or may not be ideal (eg, severe osteoporosis, certain drug interactions, eGFR &lt;15 mL/min/1.73 m
         <sup>
          2
         </sup>
         and not on hemodialysis). (See
         <a class="local">
          'Tenofovir in patients with reduced kidney function'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2150401504">
         <span class="h4">
          Choice of agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         When tenofovir should be avoided, the choice of agent used to treat HBV depends primarily upon the individual's prior treatment history.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HBV treatment-naïve
         </strong>
         – If tenofovir should be avoided in HBV treatment-naïve patients (ie, those who have never been treated with
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         , or
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         ), entecavir can be used for the treatment of HBV in combination with a fully active HIV ART regimen. Additional considerations when using entecavir are described below. (See
         <a class="local">
          'When entecavir is used'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment-experienced
         </strong>
         –
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          Entecavir
         </a>
         monotherapy is associated with a high rate of resistance in lamivudine-refractory patients. Thus, for treatment-experienced patients who cannot take tenofovir, the treatment regimen depends in large part upon the number of HBV drug-resistant mutations detected.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who have a suppressed HBV DNA or who have a detectable HBV DNA level with ≤1
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         resistance mutation (ie, rtM204V/I), we administer
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         (1 mg/day) with a fully active HIV ART regimen. (See
         <a class="local">
          'When entecavir is used'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those with multiple drug-resistant mutations (ie, the rtM204V/I mutation plus one or more
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         mutation), tenofovir remains the preferred choice for treatment of HBV, and the reasons for not using tenofovir must be reassessed. These patients should be managed in conjunction with a provider experienced in the treatment of HBV.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H202382033">
         <span class="h4">
          When entecavir is used
         </span>
         <span class="headingEndMark">
          —
         </span>
         If
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         is used for the treatment of HBV, the dose of entecavir should be adjusted in those with reduced kidney function. Dose adjustments are described in the Lexicomp drug information topic within UpToDate.
        </p>
        <p>
         In addition,
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         must be administered with a fully active HIV ART regimen. We generally prefer a nucleoside-sparing HIV ART regimen (ie, one that does
         <strong>
          not
         </strong>
         contain
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         or
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         ) for patients who are taking entecavir for the treatment of their HBV. The rationale for this approach is based upon a theoretical risk that patients who take lamivudine and entecavir together are at greater risk for the development of HBV resistance compared with those who take entecavir alone since lamivudine and entecavir share resistance mutations [
         <a href="#rid51">
          51,52
         </a>
         ]. However, since this risk is theoretical, we only use a nucleoside-sparing regimen if it is thought to be noninferior to an ART regimen that contains a nucleoside backbone. Such patients should be managed in consultation with an expert in HIV.
        </p>
        <p class="headingAnchor" id="H4123011626">
         <span class="h3">
          Avoiding regimens with lamivudine monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with HIV/HBV-coinfection may be receiving an HIV regimen that only provides
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         monotherapy for HBV (eg,
         <a class="drug drug_general" data-topicid="96759" href="/z/d/drug information/96759.html" rel="external">
          dolutegravir-abacavir-lamivudine
         </a>
         or
         <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">
          dolutegravir-lamivudine
         </a>
         ). For such patients, we modify the ART regimen to include tenofovir (TAF or TDF), unless tenofovir is contraindicated. (See
         <a class="local">
          'If tenofovir should not be used'
         </a>
         above.)
        </p>
        <p>
         When modifying a regimen, the approach depends upon the patient's viral load. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a patient has an undetectable HIV RNA and is receiving an ART regimen that uses
         <a class="drug drug_general" data-topicid="9010" href="/z/d/drug information/9010.html" rel="external">
          abacavir-lamivudine
         </a>
         as the nucleoside combination, a combination pill that contains tenofovir-emtricitabine can be substituted if the HIV RNA is suppressed and there is no known HIV resistance. (See
         <a class="local">
          'Preferred regimens'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3766.html" rel="external">
          "Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient has a detectable HIV RNA and there are concerns for HIV resistance, the HIV regimen should be optimized and tenofovir should be included if possible. These patients should be managed in conjunction with a provider experienced in the treatment of HBV and HIV. Additional considerations for patients changing their HIV regimen are described below. (See
         <a class="local">
          'Patients changing their HIV regimen'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H113872157">
         <span class="h3">
          Patients changing their HIV regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain patients will require a change in their HIV regimen. Reasons include adverse reactions to the ART regimen as well as the development of a detectable HIV RNA with HIV resistance mutations. (See
         <a class="medical medical_review" href="/z/d/html/13975.html" rel="external">
          "Evaluation of the treatment-experienced patient failing HIV therapy"
         </a>
         .)
        </p>
        <p>
         Tenofovir should be continued for the treatment of HBV when changing an HIV regimen. For patients with drug-resistant HIV, other suitable agents should be added to achieve HIV suppression. If tenofovir cannot be used (eg, adverse drug reaction), another fully active HBV agent, such as
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         , must be used in conjunction with a fully active HIV ART regimen. (See
         <a class="local">
          'If tenofovir should not be used'
         </a>
         above and
         <a class="local">
          'When entecavir is used'
         </a>
         above.)
        </p>
        <p>
         It is important to maintain optimal HBV therapy to prevent a flare of HBV as well as an immune reconstitution syndrome. This approach is particularly important for those who have cirrhosis or are hepatitis B e antigen (HBeAg)-positive and have not achieved seroconversion to hepatitis B e antibody (anti-HBe) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1539010900">
         <span class="h2">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with HIV and hepatitis B virus (HBV) coinfection will receive indefinite treatment for HIV and HBV, typically with a regimen containing tenofovir. This is based upon the chronic nature of HBV infection and the fact that patients with HIV require life-long ART. If the HIV or HBV regimen must be modified because of adverse effects, the new regimen should follow the principles outlined above. (See
         <a class="local">
          'General principles'
         </a>
         above and
         <a class="local">
          'Patients changing their HIV regimen'
         </a>
         above.)
        </p>
        <p>
         Patients should be advised against self-discontinuation of HIV or HBV treatment as withdrawal of therapy has been associated with exacerbations of hepatitis and hepatic failure in up to 30 percent of patients [
         <a href="#rid47">
          47,53-56
         </a>
         ]. This is particularly important in patients with cirrhosis to avoid developing the complications associated with untreated HBV.
        </p>
        <p>
         A limited number of patients will become hepatitis B surface antigen (HBsAg)-negative and hepatitis B surface antibody (anti-HBs)-positive following prolonged suppressive therapy, and these individuals are functionally cured. We continue such patients on anti-HBV therapy for an additional 12 months to increase the likelihood of a durable response, after which anti-HBV therapy can be discontinued (provided they do not have cirrhosis). This approach is supported by the Asian-Pacific consensus statement on the management of chronic hepatitis B [
         <a href="#rid57">
          57
         </a>
         ]. However, patients who discontinue treatment for HBV
         <strong>
          must
         </strong>
         be maintained on a fully suppressive HIV regimen. In addition, they must be monitored closely for a relapse of their HBV infection. (See
         <a class="local">
          'Monitoring therapy for HBV'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1162479359">
         <span class="h1">
          MONITORING THERAPY FOR HBV
         </span>
        </p>
        <p class="headingAnchor" id="H4087003892">
         <span class="h2">
          What to monitor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical evaluation and laboratory monitoring are important to evaluate the efficacy of hepatitis B virus (HBV) treatment as well as potential toxicity. A detailed discussion regarding patient monitoring for HBV is found elsewhere and summarized below. (See
         <a class="medical medical_review" href="/z/d/html/16129.html" rel="external">
          "Monitoring the patient with HIV and chronic hepatitis B virus infection"
         </a>
         .)
        </p>
        <p>
         Briefly, we monitor:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical signs and symptoms of hepatitis (right upper quadrant pain, nausea, vomiting, fatigue, jaundice, loss of appetite).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HBV DNA every three months until undetectable for at least two consecutive visits. We then decrease the frequency to every six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aminotransferases every three months as a marker of drug-induced hepatotoxicity, immune reconstitution, or disease activity. The frequency can be decreased to every six months in patients with an undetectable HBV DNA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatitis B e antigen (HBeAg) and hepatitis B e antibody (anti-HBe) every six months in patients who are HBeAg-positive to determine if seroconversion has occurred. If HBeAg seroconversion has occurred, we repeat the HBeAg to confirm the result. We do not monitor the HBeAg after that unless there is an increase in the aminotransferase levels or antiretroviral therapy (ART) is stopped with a subsequent increase in the HIV RNA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening for hepatocellular carcinoma.
        </p>
        <p>
        </p>
        <p>
         We also check other laboratory studies (eg, serum creatinine, urinalysis) according to the guidelines for the monitoring of HIV-infected patients receiving ART [
         <a href="#rid5">
          5
         </a>
         ]. A detailed discussion of laboratory monitoring for patients receiving ART is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">
          "Patient monitoring during HIV antiretroviral therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H834875469">
         <span class="h2">
          Response to therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of treatment is complete suppression of HBV DNA by a sensitive polymerase chain reaction (PCR)-based assay. For patients on tenofovir or
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         , we expect a 1 log
         <sub>
          10
         </sub>
         decline in HBV DNA after 12 weeks of treatment and, for most patients, a suppressed HBV DNA by one year. Compared with HIV, viral suppression of HBV can take longer to achieve. (See
         <a class="local">
          'Tenofovir'
         </a>
         above.)
        </p>
        <p>
         If a patient is on tenofovir or
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         and does not achieve a 1 log
         <sub>
          10
         </sub>
         decline in HBV DNA by 12 weeks:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We assess for factors that could lead to subtherapeutic drug levels, such as suboptimal adherence, poor absorption, and/or drug interactions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition, we perform resistance testing in patients who are receiving
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         monotherapy if they had been previously treated with
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         ; this group is at high risk for treatment failure. (See
         <a class="local">
          'If tenofovir should not be used'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         If a patient is on tenofovir or
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         and the HBV DNA is &gt;2000 international units/mL after receiving therapy for approximately two years [
         <a href="#rid58">
          58
         </a>
         ], we use the following approach:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We assess for factors that could lead to subtherapeutic drug levels, such as suboptimal adherence, poor absorption, and/or drug interactions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We check a resistance profile in patients receiving
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         to confirm that there are no entecavir mutations present. Resistance testing is not usually helpful in such patients receiving tenofovir, since tenofovir resistance mutations for HBV are very rare [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with cirrhosis, and no evidence of resistance, we add a second agent (eg,
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         to a tenofovir-containing regimen [
         <a href="#rid60">
          60,61
         </a>
         ]) in order to obtain more rapid viral suppression.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients without cirrhosis, and no evidence of resistance, we continue to monitor the HBV DNA and alanine transaminase (ALT). Most patients will suppress their HBV DNA within five years [
         <a href="#rid20">
          20,62
         </a>
         ]. However, for those with continued ALT elevations without another cause, we add
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         since ongoing ALT elevations suggest ongoing injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If there is evidence of viral resistance to
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         , the use of tenofovir should be reassessed. The approach to patients who cannot take tenofovir is described above. (See
         <a class="local">
          'If tenofovir should not be used'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3855742907">
         <span class="h2">
          Renal insufficiency on tenofovir
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tenofovir is associated with worsening kidney function in some patients. When this occurs, tenofovir usually causes chronic renal insufficiency secondary to a proximal tubulopathy [
         <a href="#rid63">
          63
         </a>
         ]. Renal insufficiency is more likely to occur in patients receiving
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         (TDF) compared with
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         (TAF). (See
         <a class="local">
          'Tenofovir'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">
          "Overview of kidney disease in patients with HIV", section on 'Medication nephrotoxicity'
         </a>
         .)
        </p>
        <p>
         For patients who were initially receiving TDF, we switch TDF to TAF as soon as the estimated glomerular filtration rate (eGFR) falls below 60 mL/min/1.73 m
         <sup>
          2
         </sup>
         (
         <a class="calc calc_professional" href="/z/d/html/15635.html" rel="external">
          calculator 1
         </a>
         ). However, if the patient is unable to take a TAF-containing regimen (eg, drug interactions, concerns that even TAF would continue to produce renal toxicity), the approach to treatment depends upon the presence of HBV drug resistance mutations as described above. (See
         <a class="local">
          'Tenofovir in patients with reduced kidney function'
         </a>
         above and
         <a class="local">
          'If tenofovir should not be used'
         </a>
         above.)
        </p>
        <p>
         We discontinue tenofovir and start
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         with fully suppressive HIV ART regimen in all patients who develop acute kidney injury or a Fanconi-like syndrome, regardless of the eGFR and baseline HBV status. The rationale for this is based upon the serious complications, including end-stage kidney disease and death, that may occur in individuals with HIV who developed these complications [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3954652388">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">
          "Society guideline links: Opportunistic infections in adults with HIV"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/111626.html" rel="external">
          "Society guideline links: Management of hepatitis B"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H92573915">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15382.html" rel="external">
          "Patient education: Hepatitis B (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4575.html" rel="external">
          "Patient education: Hepatitis B (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H45">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – Patients with HIV and chronic hepatitis B virus (HBV) infection should receive treatment to suppress both viruses regardless of HBV DNA level or degree of liver damage. Such patients should be treated with a regimen that is effective against
         <strong>
          both
         </strong>
         HBV and HIV. (See
         <a class="local">
          'General principles'
         </a>
         above and
         <a class="local">
          'Rationale for treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred regimens
         </strong>
         – For patients with HIV/HBV coinfection and an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we recommend a tenofovir-containing antiretroviral therapy (ART) regimen (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Tenofovir is considered a first-line agent for treatment of HIV and HBV because the virologic efficacy is high and the risk of resistance is low; it is also effective for the treatment of HBV in patients who have lamivudine-resistant virus. (See
         <a class="local">
          'Antiviral Medications for HBV'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most patients with HIV/HBV coinfection, our preferred ART regimen is
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         plus
         <a class="drug drug_general" data-topicid="107645" href="/z/d/drug information/107645.html" rel="external">
          tenofovir alafenamide-emtricitabine
         </a>
         or
         <a class="drug drug_general" data-topicid="116731" href="/z/d/drug information/116731.html" rel="external">
          bictegravir-emtricitabine-tenofovir alafenamide
         </a>
         . Selecting an ART regimen is discussed in detail in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129782.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naive persons with HIV-1: Patients with comorbid conditions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         TDF can be used instead of TAF for most patients with normal renal function (eGFR ≥60 mL/min/1.73 m
         <sup>
          2
         </sup>
         ) if TAF is not available or should be avoided (eg, because of drug interactions); however, the risk of kidney disease and bone loss is greater with TDF compared with TAF. (See
         <a class="local">
          'Preferred regimens'
         </a>
         above and
         <a class="local">
          'Tenofovir in patients with reduced kidney function'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with severely reduced kidney function (eGFR &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         ), regimen selection depends upon the degree of renal insufficiency and the patient's prior treatment history. (See
         <a class="local">
          'Tenofovir in patients with reduced kidney function'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternative regimens
         </strong>
         – On rare occasion, when tenofovir should not be used,
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         may be reasonable for treatment of HBV in those who are at low risk of drug-resistant HBV. However, entecavir is associated with a high rate of HBV resistance in patients with lamivudine-resistant virus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If a patient is treated with
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         for HBV, it
         <strong>
          must
         </strong>
         be administered in conjunction with a fully active HIV ART regimen. For such patients, we generally prefer a nucleoside-sparing regimen for the treatment of their HIV (ie, one that does not contain
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         or
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         ). There is a theoretic risk that patients who take lamivudine and entecavir together are at greater risk for the development of HBV resistance compared with those who take entecavir alone. (See
         <a class="local">
          'If tenofovir should not be used'
         </a>
         above and
         <a class="local">
          'When entecavir is used'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoiding regimens with
         </strong>
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         <strong>
          monotherapy
         </strong>
         – We
         <strong>
          avoid
         </strong>
         an HIV ART regimen that uses lamivudine monotherapy for the treatment of HBV (eg,
         <a class="drug drug_general" data-topicid="96759" href="/z/d/drug information/96759.html" rel="external">
          dolutegravir-abacavir-lamivudine
         </a>
         ,
         <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">
          dolutegravir-lamivudine
         </a>
         ) because of the rapid emergence of lamivudine-resistant HBV. If a patient is receiving an HIV regimen that only provides lamivudine monotherapy for HBV, we modify the ART regimen to include tenofovir. (See
         <a class="local">
          'Avoiding regimens with lamivudine monotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Considerations when changing HIV regimens
         </strong>
         – For patients who require a change in their HIV regimen, tenofovir should be continued, if possible. If tenofovir cannot be used (eg, adverse drug reaction), another fully active HBV agent (eg,
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         ) must be used in conjunction with a fully active HIV ART regimen. (See
         <a class="local">
          'Patients changing their HIV regimen'
         </a>
         above and
         <a class="local">
          'When entecavir is used'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of treatment
         </strong>
         – Most patients with HIV/HBV coinfection will receive life-long treatment for HIV and HBV with an ART regimen containing tenofovir. This is based upon the chronic nature of HBV infection and the fact that patients with HIV require life-long ART. Patients should be advised against self-discontinuation of treatment as withdrawal of therapy has been associated with exacerbations of hepatitis and hepatic failure. (See
         <a class="local">
          'Duration of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring on treatment
         </strong>
         – Clinical evaluation and laboratory monitoring are important to evaluate the efficacy of HBV treatment as well as potential toxicity. This is discussed in detail in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/16129.html" rel="external">
          "Monitoring the patient with HIV and chronic hepatitis B virus infection"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA 2018; 320:379.
          </a>
         </li>
         <li class="breakAll">
          European guidelines for treatment of HIV-infected adults. Available at: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html (Accessed on July 24, 2023).
         </li>
         <li class="breakAll">
          World Health Organization. Guidelines for the prevention, care and treatment of persons living with chronic hepatitis B http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1 (Accessed on March 23, 2015).
         </li>
         <li class="breakAll">
          Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adulrs and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on October 09, 2017).
         </li>
         <li class="breakAll">
          Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on January 16, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockdale AJ, Phillips RO, Beloukas A, et al. Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana. Clin Infect Dis 2015; 61:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rana U, Driedger M, Sereda P, et al. Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada? BMC Infect Dis 2019; 19:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soriano V, Poveda E, Vispo E, Barreiro P. Hepatitis B in HIV-infected patients. Clin Liver Dis 2013; 17:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49:S138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puoti M, Torti C, Bruno R, et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44:S65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo Re V 3rd, Newcomb CW, Carbonari DM, et al. Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. J Acquir Immune Defic Syndr 2019; 82:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crane M, Oliver B, Matthews G, et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis 2009; 199:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen Stuart JW, Velema M, Schuurman R, et al. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 2009; 81:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price H, Dunn D, Pillay D, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One 2013; 8:e68152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyd A, Lasnier E, Molina JM, et al. Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther 2010; 15:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martín-Carbonero L, Teixeira T, Poveda E, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011; 25:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puoti M, Cozzi-Lepri A, Paraninfo G, et al. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther 2006; 11:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Núñez M, Pérez-Olmeda M, Díaz B, et al. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16:2352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 2003; 17:F7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186:1844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bihl F, Martinetti G, Wandeler G, et al. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterol 2015; 15:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park ES, Lee AR, Kim DH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol 2019; 70:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385:2606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surial B, Béguelin C, Chave JP, et al. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study. J Acquir Immune Defic Syndr 2020; 85:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallon PWG, Brunet L, Fusco JS, et al. Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides. Open Forum Infect Dis 2022; 9:ofab621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murakami E, Wang T, Park Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother 2015; 59:3563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal K, Fung SK, Nguyen TT, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol 2015; 62:533.
          </a>
         </li>
         <li class="breakAll">
          Liu Y, Mitchell BC, Dinh P, et al. Antiviral activity of tenofovir alafenamide (TAF) against
drug resistant HBV isolates in vitro. Presented at the American Association for the Study of Liver Diseases. San Francisco. 2015
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallant J, Brunetta J, Crofoot G, et al. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. J Acquir Immune Defic Syndr 2016; 73:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001; 32:963.
          </a>
         </li>
         <li class="breakAll">
          Snow, A, Harris, J, Borroto-Esoda, K, et al. Emtricitabine therapy for hepatitis infection in HIV+ patients co-infected with hepatitis B virus: efficacy and genotypic findings in antiretroviral treatment-naive patients. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, Boston, MA Abstract #836.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dore GJ, Cooper DA, Barrett C, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 2007; 12 Suppl 3:H15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eron JJ Jr, Lelievre JD, Kalayjian R, et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Lancet HIV 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48:3498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altfeld M, Rockstroh JK, Addo M, et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998; 29:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGovern B. What drives hepatitis B virus-related hepatic flares? Virus, T cells--or a bit of both? Clin Infect Dis 2004; 39:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dore GJ, Soriano V, Rockstroh J, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 2010; 24:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellini C, Keiser O, Chave JP, et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med 2009; 10:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blackard JT, Kwara A, Sherman KE. In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol 2019; 71:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikulska M, Taramasso L, Giacobbe DR, et al. Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. J Med Virol 2012; 84:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratcliffe L, Beadsworth MB, Pennell A, et al. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 2011; 25:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang YJ, Shim JH, Kim KM, et al. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology 2014; 59:1303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol 2013; 24:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008; 22:99.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3652 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30043070" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30043070" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30043070" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30043070" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30043070" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26021992" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23234725" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31752729" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23905818" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Hepatitis B in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10094979" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12454838" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19399813" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hepatitis B and human immunodeficiency virus coinfection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16338021" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Natural history of chronic hepatitis B in co-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12493258" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10969344" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Mortality for liver disease in patients with HIV infection: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15802978" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31107304" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19231993" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19152397" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23874527" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21041911" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21076274" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16964824" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12519935" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15031786" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12441815" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12478090" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12447773" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26152237" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30794889" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25890673" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32925387" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35028335" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25870059" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25450717" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25450717" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27171740" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28404091" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28404092" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19280622" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11247719" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11247719" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10438346" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8929003" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16549970" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10534354" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10452630" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18284179" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10827158" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30555051" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16673294" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Antiviral drug resistance: clinical consequences and molecular aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15328117" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9722213" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15206065" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : What drives hepatitis B virus-related hepatic flares? Virus, T cells--or a bit of both?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20216301" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18795964" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26563120" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29405329" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31564447" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22825811" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21346511" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24170683" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24052632" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18260800" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
